Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.

MLA

Bath, Philip M., et al. “Antiplatelet Therapy with Aspirin, Clopidogrel, and Dipyridamole versus Clopidogrel Alone or Aspirin and Dipyridamole in Patients with Acute Cerebral Ischaemia (TARDIS): A Randomised, Open-Label, Phase 3 Superiority Trial.” Lancet (London, England), vol. 391, no. 10123, Mar. 2018, pp. 850–59. EBSCOhost, https://doi.org/10.1016/S0140-6736(17)32849-0.

APA

Bath, P. M., Woodhouse, L. J., Appleton, J. P., Beridze, M., Christensen, H., Dineen, R. A., Duley, L., England, T. J., Flaherty, K., Havard, D., Heptinstall, S., James, M., Krishnan, K., Markus, H. S., Montgomery, A. A., Pocock, S. J., Randall, M., Ranta, A., Robinson, T. G., … Sprigg, N. (2018). Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. Lancet (London, England), 391(10123), 850–859. https://doi.org/10.1016/S0140-6736(17)32849-0

Chicago

Bath, Philip M, Lisa J Woodhouse, Jason P Appleton, Maia Beridze, Hanne Christensen, Robert A Dineen, Lelia Duley, et al. 2018. “Antiplatelet Therapy with Aspirin, Clopidogrel, and Dipyridamole versus Clopidogrel Alone or Aspirin and Dipyridamole in Patients with Acute Cerebral Ischaemia (TARDIS): A Randomised, Open-Label, Phase 3 Superiority Trial.” Lancet (London, England) 391 (10123): 850–59. doi:10.1016/S0140-6736(17)32849-0.